BioCryst halts enrollment in all studies for its lead pipeline candidate — shares crash
BioCryst is taking a beating Friday morning after reporting it would pause enrollment in three studies for its lead pipeline program.
In a terse statement put out right before the market opened, the Durham, NC-based biotech said it discovered elevated serum creatinine levels in some patients, and will halt recruitment while it investigates. Elevated creatine levels can be a sign of kidney dysfunction.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.